Cara Therapeutics (CARA) Misses Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cara Therapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 4:01 PM EDTReported statistically-significant positive top-line results from Phase 2 trial for I.V. CR845 in uremic pruritus
Completed successful public offering of common stock, raising net proceeds of $75.1 million
First Pivotal trial for I.V. CR845 in acute pain on track to begin in 3Q'15
Conference call today at 4:30 p.m. ET
SHELTON, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ: CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by... More
